RESULTS	There were significantly greater improvements in the mean percentage change in FEV ( 1 ) AUC ( 0-12h ) from the predose value over 12 weeks ( 15 microg BID , 12.7 % , 25 microg BID , 13.9 % , 50 microg QD , 18.9 % ; salmeterol , 9.8 % ) versus placebo ( 2.7 % ; P < or = 0.001 ) ; all doses of arformoterol were statistically different from salmeterol for this end point ( P < or = 0.024 ) .\